Moyamoya Disease

1. Executive Overview: Understanding Moyamoya Disease

Moyamoya disease (MMD) is a rare, progressive cerebrovascular disorder characterized by the narrowing (stenosis) of the internal carotid arteries and their major branches at the base of the brain. The term "Moyamoya" is Japanese for "puff of smoke," describing the characteristic angiographic appearance of the compensatory, fragile collateral vessels that form as the brain attempts to bypass the blocked arteries.

Classified under ICD-10 code I67.5, this condition poses a significant risk for ischemic stroke due to hypoperfusion, as well as hemorrhagic stroke due to the rupture of fragile, dilated collateral vessels. It is a condition that requires specialized neurosurgical intervention and long-term neurological monitoring.

2. Pathophysiology, Etiology, and Risk Factors

The pathophysiology of Moyamoya disease centers on the chronic, progressive occlusion of the distal internal carotid artery (ICA) and the proximal segments of the anterior and middle cerebral arteries.

Pathophysiological Mechanism

As the primary intracranial arteries narrow, the brain experiences chronic ischemia. In response, the body develops a dense network of thin-walled, fragile collateral vessels—the "Moyamoya vessels"—which represent a compensatory mechanism to maintain cerebral blood flow (CBF). Unfortunately, these vessels are prone to aneurysm formation and rupture, leading to intracranial hemorrhage.

Etiology and Genetics

While the exact cause remains idiopathic in many cases, significant evidence points to a genetic predisposition. The RNF213 gene has been identified as a major susceptibility factor, particularly in East Asian populations.

Risk Factors

• Demographics: Higher prevalence in East Asian populations (Japan, Korea, China).
• Age: Bimodal distribution, peaking in childhood (first decade) and adulthood (fourth decade).
• Gender: Slight female predominance.

3. Signs, Symptoms, and Clinical Presentation

The clinical manifestation of Moyamoya disease varies significantly between children and adults.

Pediatric Presentation

Children typically present with ischemic symptoms. Common triggers include hyperventilation (crying, blowing up balloons, or intense physical activity), which causes hypocapnia-induced cerebral vasoconstriction, further reducing blood flow through already narrowed vessels.
* Transient Ischemic Attacks (TIAs)
* Ischemic stroke
* Seizures
* Developmental delay or cognitive decline

Adult Presentation

Adults are more likely to present with hemorrhagic symptoms due to the rupture of the fragile collateral vessels.
* Intracerebral hemorrhage (ICH)
* Intraventricular hemorrhage
* Subarachnoid hemorrhage
* Severe headaches and migraines
* Neurological deficits (hemiparesis, sensory impairment)

4. Standard Diagnostic Evaluation and Workup

Early and accurate diagnosis is critical to prevent permanent neurological damage. The gold standard for diagnosis is Digital Subtraction Angiography (DSA).

Diagnostic Modalities

1. Magnetic Resonance Imaging (MRI) & MRA: Used as the initial screening tool to visualize arterial narrowing and the "puff of smoke" appearance.
2. Digital Subtraction Angiography (DSA): The gold standard. It provides high-resolution visualization of the carotid artery stenosis and the collateral network.
3. Perfusion Studies (SPECT, PET, or CT Perfusion): Essential to evaluate cerebral blood flow and cerebrovascular reserve (CVR). These tests determine how well the brain can compensate for reduced blood flow under stress (e.g., after acetazolamide administration).
4. Transcranial Doppler (TCD): Used for non-invasive longitudinal monitoring of blood flow velocities in the major intracranial arteries.

The Suzuki Staging System

The severity of MMD is typically graded using the Suzuki scale:
* Stage I: Narrowing of the carotid fork.
* Stage II: Initiation of Moyamoya vessels.
* Stage III: Intensification of Moyamoya vessels.
* Stage IV: Minimization of Moyamoya vessels.
* Stage V: Reduction of Moyamoya vessels.
* Stage VI: Disappearance of Moyamoya vessels; blood supply via external carotid artery.

5. Therapeutic Interventions

There is currently no cure for Moyamoya disease. Treatment is focused on restoring blood flow and preventing future strokes.

Surgical Revascularization (Standard of Care)

Surgery is the primary treatment for symptomatic MMD to improve cerebral perfusion.
* Direct Bypass: Superficial temporal artery to middle cerebral artery (STA-MCA) anastomosis. This provides immediate blood flow augmentation.
* Indirect Bypass: Procedures like EDAS (Encephaloduroarteriosynangiosis) or EMS (Encephalomyosynangiosis). These involve placing vascularized tissue (like muscle or dura) onto the brain surface to encourage the growth of new blood vessels over time.
* Combined Bypass: Utilizing both direct and indirect techniques for optimal long-term results.

Pharmacotherapy

While surgery is definitive, medications are used for symptom management and stroke risk reduction:
* Antiplatelet Agents: Aspirin is commonly used in patients with ischemic presentation to prevent micro-thrombi formation.
* Calcium Channel Blockers: May be used to manage headaches or reduce vasospasm.
* Anticonvulsants: Required if the patient has experienced seizures.

Lifestyle and Long-Term Prognosis

• Stroke Prevention: Rigorous blood pressure control and avoidance of dehydration.
• Activity Modification: Patients are often advised to avoid activities that involve hyperventilation or vigorous contact sports.
• Prognosis: With surgical intervention, the risk of stroke is significantly reduced. However, long-term neuroimaging follow-up is mandatory to monitor for disease progression or graft patency.

6. Frequently Asked Questions (FAQ)

1. Is Moyamoya disease hereditary?
Yes, while most cases are sporadic, there is a genetic component. The RNF213 gene mutation is linked to a higher risk, and family clusters have been documented.

2. Is Moyamoya a type of stroke?
No, it is a vascular disease that causes strokes. It leads to both ischemic strokes (from lack of blood) and hemorrhagic strokes (from bursting vessels).

3. What is the "puff of smoke" appearance?
It refers to the angiographic appearance of the tiny, tangled collateral vessels that grow to compensate for the blocked main arteries in the brain.

4. Can Moyamoya be cured with medication alone?
No. Medication can help manage symptoms or reduce risk, but surgery is the only way to effectively re-establish adequate blood flow to the brain.

5. What happens if Moyamoya is left untreated?
Untreated MMD is progressive and carries a high risk of recurrent strokes, cognitive impairment, and, in severe cases, death due to massive intracranial hemorrhage.

6. At what age is Moyamoya usually diagnosed?
It has a bimodal distribution, meaning it is most commonly diagnosed in children (ages 5–10) and adults (ages 30–50).

7. Is surgery for Moyamoya safe?
When performed by experienced neurovascular surgeons, revascularization surgery has high success rates in improving blood flow and reducing the risk of future strokes.

8. Do I need to make lifestyle changes?
Yes. Patients should avoid activities that cause hyperventilation, maintain optimal hydration, and manage blood pressure strictly.

9. How often should I get checked after surgery?
Regular follow-up with MRI/MRA or perfusion imaging is required—typically every 6 to 12 months in the first few years post-surgery—to ensure the bypass is working.

10. Does Moyamoya affect children differently than adults?
Yes. Children usually present with ischemic symptoms (TIAs/strokes), whereas adults are more prone to hemorrhagic strokes due to the fragility of the collateral vessels.